

**AMENDMENTS TO THE CLAIMS**  
**37 C.F.R §1.121(c)**

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application. Underlining denotes added text, and strikethrough denotes cancelled text.

**1-24. (Canceled)**

**25. (Currently Amended)** A method for reducing angiogenesis in a tissue, comprising:

- a) providing:
  - i) a tissue comprising endothelial cells; and
  - ii) an isolated nucleotide sequence encoding a protein comprising a protein kinase A (PKA) catalytic subunit; and
- b) expressing said nucleotide sequence in said endothelial cells to produce a treated tissue, such that angiogenesis by said endothelial cells in said treated tissue is reduced.

**26. (Previously Presented)** The method of Claim 25, further comprising step c) detecting a reduction in angiogenesis in said treated tissue.

**27. (Previously Presented)** The method of Claim 25, wherein said tissue is in a subject.

**28. (Previously Presented)** The method of Claim 27, wherein said subject has angiogenesis in said tissue.

**29. (Previously Presented)** The method of Claim 27, wherein said tissue comprises a tumor.

**30. (Previously Presented)** The method of Claim 29, wherein said tumor is malignant.

**31. (Previously Presented)** The method of Claim 30, wherein said malignant tumor is metastatic.

32. (Previously Presented) The method of Claim 27, wherein said subject has a pathological condition associated with angiogenesis in said tissue.

33. (Previously Presented) A method for increasing apoptosis, comprising:

- a) providing:
  - i) a tissue comprising cells; and
  - ii) an isolated nucleotide sequence encoding a protein comprising a protein kinase A (PKA) catalytic subunit; and
- b) expressing said nucleotide sequence in said cells such that apoptosis of said cells is increased.

34. (Previously Presented) The method of Claim 33, further comprising step c) detecting an increase in apoptosis in said cells.

35. (Previously Presented) The method of Claim 33, wherein said tissue is in a subject.

36. (Previously Presented) The method of Claim 33, wherein said cell is chosen from endothelial cell, vascular smooth muscle cell, monocyte cell, macrophage cell, benign tumor cell, malignant tumor cell, fibroblast cell, B cell, T cell, myocyte cell, megakaryocyte cell, eosinophil cell, neurite cell, and synoviocyte cell.

37. (Previously Presented) The method of Claim 35, wherein said subject has a pathological condition chosen from angiogenesis, restenosis, atherosclerosis, cancer, tumor metastasis, fibrosis, hemangioma, lymphoma, leukemia, psoriasis, arthritis, autoimmune disease, diabetes, amyotrophic lateral sclerosis, graft rejection, retinopathy, macular degeneration, and retinal tearing.

38. (Previously Presented) The method of Claim 33, wherein said tissue comprises a tumor.

39. (**Previously Presented**) The method of Claim 38, wherein said tumor is malignant.

40. (**Previously Presented**) The method of Claim 39, wherein said malignant tumor is metastatic.